Amongst parkinsonian symptoms tremor is poorly controlled by drug therapy. As a matter of fact, the administration of L-Dopa + DDI shows a partial improvement in tremor. The biochemical mechanism underlying tremor is not yet indentified, but seems to be different from akinesia and rigidity. A neuropharmacological study was performed to investigate the mechanism involved in tremor. An evaluation of the efficacy of dopaminergic drugs and particularly of piribedil is presented. 27 idiopathic hyperkinetic Parkinsonian subjects have been studied. Owing to the fact that precursors (Dopa) are generally able to utilise common enzymatic mechanism (aromatic decarboxylase) receptor agonists and antagonists were used acutely. Tremor was evaluated by a piezoelectric accelerometer and continuously recorded. Among dopaminergic agents, piribedil (0.021 mg/kg) is able to control the parkinsonian tremor. This activity is maximal 10 minutes after administration, decreasing after 30 mins. After 10 mins piribedil was the most active agent among considered.
|Translated title of the contribution||Dopaminergic drugs in the treatment of Parkinsonian tremor|
|Number of pages||6|
|Publication status||Published - 1979|
ASJC Scopus subject areas
- Psychiatry and Mental health